Navigation Links
Researchers Discover How Antibiotic Inhibits Bacterial Growth

Researchers at the University of Illinois at Chicago, in collaboration with research teams from Pharmacia & Upjohn and Pfizer, have discovered precisely how the antibiotic linezolid inhibits bacterial growth.

Scientists have known that the drug linezolid -- the first new antibiotic to enter the marketplace in 30 years -- works by binding to ribosomes, the protein production factory of the cell. But exactly where the binding occurred and how the drug worked was not known. Until now.

"Linezolid targets ribosomes, inhibits protein synthesis, and kills bacteria," said Alexander Mankin, professor and associate director of UIC's Center for Pharmaceutical Biotechnology and lead investigator of the study. "If we know exactly where the drug binds, we can make it better and learn how to use it more effectively."

Linezolid is a synthetic antibiotic used for the treatment of infections caused by pathogens such as staph and strep, including multi-drug-resistant bacteria. Skin infections, pneumonia, and other diseases can be treated with linezolid. It is marketed in the United States as Zyvox.

Mankin and his colleagues managed not only to crosslink the drug to its target in the living cell, but to precisely characterize the mode of binding of the drug to the ribosome.

"It was a combined effort of excellent chemists, structural biologists and biochemists," Mankin said.

"We now understand much better how the drug works, how it can be improved, and how bacteria can become resistant to linezolid."

A second part of the study involved learning why, in rare cases, the drug can have side effects causing a decrease in the production of blood cells. By crosslinking linezolid to its target in human cells, the researchers showed that the drug may be toxic to mitochondria -- the power generators of the cell -- which contain ribosomes that resemble the ribosomes of bacteria.

"This i s the first time such detailed information about the linezolid target in the living cell has been obtained," Mankin said.


'"/>




Related medicine news :

1. Researchers urge caution in using ear tube surgery
2. Researchers Scale to assess the Severity of Epilepsy in Kids
3. Researchers trick Alzheimers Enzyme
4. Researchers find new HIV hiding place
5. New Hair in 15 Days Could Now Be A Possibility Say Researchers
6. Researchers developed world’s smallest toothbrus
7. Researchers discover receptor cells that can cause epilepsy
8. 15 Anti-SARS Drugs Identified By China-Europe Team of Researchers
9. Researchers reversed the process of memory loss
10. Researchers Identify Key Gene That May Help Brain Treatment
11. Researchers Discover Protein That Causes Malaria
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance ... care insurance companies have a waiver for care if the client has a cognitive ... the family pays for care, is often waived, so the benefits from their insurance ...
(Date:10/13/2017)... Texas (PRWEB) , ... October 13, 2017 , ... Yisrayl ... this week that explains one of the most popular and least understood books in ... like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian history ... The Brink” is the creation of published author, William Nowers. Captain Nowers and ... WWII veteran, he spent thirty years in the Navy. Following his career as ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... the demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults ... tested to meet the highest standard. , These products are also: Gluten ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the ... to develop to enable prevention of a major side effect of chemotherapy in ... in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... Israel and NEW YORK , Sept. 27, ... with mobile health and big data solutions, today announced that its MyDario ... Please check your local TV listings for when The Dr. Oz Show ... ... season this month. ...
(Date:9/23/2017)... Pa. , Sept. 22, 2017 Janssen ... a complete response letter from the U.S. Food and ... seeking approval of sirukumab for the treatment of moderately ... letter indicates additional clinical data are needed to further ... moderately to severely active RA. ...
(Date:9/19/2017)... Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that uses ... today:   ... Jim ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led R&D and business ...
Breaking Medicine Technology: